Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 17 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Fasting serum gastrin levels can predict outcome in Zollinger-Ellison Syndrome patients

In patients with Zollinger-Ellison Syndrome, severity of fasting serum gastrin at presentation is associated with size and site of tumor, and the presence of hepatic metastases, according to research in the Journal of Clinical Oncology.

News image

fiogf49gjkf04

A team from Bethesda, Maryland, USA, assessed the prognostic value of initial fasting serum gastrin (FSG) levels in patients with Zollinger-Ellison Syndrome (ZES). They investigated whether they could be used to predict primary tumor characteristics and survival.

A total of 239 patients were treated for ZES between 1981 and 1998, with a mean follow-up of 9 years.

At initial evaluation, 36% of patients had mild (0 to 499 pg/mL), 26% had moderate (500 to 1,000 pg/mL), and 39% had severe (>1,000 pg/mL) elevations in FSG.

In sporadic ZES patients, initial fasting gastrin related to:
- tumor size
- primary tumor location
- frequency of lymph node/liver metastasis
- survival
Journal of Clinical Oncology

Primary tumor location and size, presence of lymph node or hepatic metastases, and survival were analyzed, based on the level of initial FSG.

In patients with sporadic ZES, there was a significant relationship between the level of initial FSG and tumor size and location of primary tumor, frequency of lymph node and liver metastases, and survival. This was not the case in those with multiple endocrine neoplasia type 1 (MEN-1) and ZES

The researchers found that the median 5- and 10-year survival decreased with increasing initial FSG, in patients with sporadic ZES. MEN-1 patients lived longer than sporadic ZES patients, and survival in this group was not associated with the level of initial FSG.

Multivariate analysis was used to determine the factors independently associated with death from disease, in patients with sporadic ZES. These were liver metastases, a pancreatic site, and primary tumor size, but not initial FSG.

Adam C. Berger, of the National Institutes of Health, Bethesda, said on behalf of the group, "The severity of fasting serum gastrin at presentation is associated with size and site of tumor, and the presence of hepatic metastases. These factors are significant independent predictors of outcome."

"The level of FSG at presentation may be useful in planning the nature and extent of the initial evaluation and management, in patients with sporadic ZES," he concluded.

J Clin Oncol 2001; 19 (12): 3051-7
20 June 2001

Go to top of page Email this page Email this page to a colleague

 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us